awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q33431019-5355431F-80B1-4D67-A5B1-AB7711671E1D
Q33431019-5355431F-80B1-4D67-A5B1-AB7711671E1D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33431019-5355431F-80B1-4D67-A5B1-AB7711671E1D
A retrospective analysis of efficacy and safety of adding bevacizumab to chemotherapy as first- and second-line therapy in advanced non-small-cell lung cancer (NSCLC).
P2860
Q33431019-5355431F-80B1-4D67-A5B1-AB7711671E1D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33431019-5355431F-80B1-4D67-A5B1-AB7711671E1D
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
1b288e43f44bddb8d7ba47753bac319637d2aeb1
P2860
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.